Ardelyx (ARDX) Competitors

$6.38 -0.23 (-3.48%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$6.42 +0.04 (+0.71%)

As of 06:54 AM Eastern

ARDX vs. ACLX, KYMR, PTGX, COGT, and BLTE

Should you buy Ardelyx stock or one of its competitors? MarketBeat compares Ardelyx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ardelyx include Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Cogent Biosciences (COGT), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Ardelyx compare to Arcellx?

Arcellx (NASDAQ:ACLX) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Arcellx currently has a consensus price target of $111.87, indicating a potential downside of 2.78%. Ardelyx has a consensus price target of $15.70, indicating a potential upside of 146.08%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Ardelyx has a net margin of -13.58% compared to Arcellx's net margin of -1,027.26%. Ardelyx's return on equity of -38.11% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-1,027.26%	-55.42%	-36.24%
Ardelyx	-13.58%	-38.11%	-11.85%

Arcellx has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

96.0% of Arcellx shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 8.4% of Arcellx shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ardelyx has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A
Ardelyx	$427.68M	3.69	-$61.60M	-$0.23	N/A

In the previous week, Ardelyx had 7 more articles in the media than Arcellx. MarketBeat recorded 7 mentions for Ardelyx and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Ardelyx's score of 1.05 indicating that Arcellx is being referred to more favorably in the media.

Company	Overall Sentiment
Arcellx	Positive
Ardelyx	Positive

Summary

Ardelyx beats Arcellx on 12 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Kymera Therapeutics currently has a consensus price target of $118.10, suggesting a potential upside of 37.98%. Ardelyx has a consensus price target of $15.70, suggesting a potential upside of 146.08%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

58.9% of Ardelyx shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ardelyx has higher revenue and earnings than Kymera Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	179.56	-$311.35M	-$3.57	N/A
Ardelyx	$427.68M	3.69	-$61.60M	-$0.23	N/A

Ardelyx has a net margin of -13.58% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Ardelyx	-13.58%	-38.11%	-11.85%

In the previous week, Kymera Therapeutics had 4 more articles in the media than Ardelyx. MarketBeat recorded 11 mentions for Kymera Therapeutics and 7 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.05 beat Kymera Therapeutics' score of 0.32 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

Kymera Therapeutics and Ardelyx tied by winning 8 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Protagonist Therapeutics?

Ardelyx (NASDAQ:ARDX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, Protagonist Therapeutics had 8 more articles in the media than Ardelyx. MarketBeat recorded 15 mentions for Protagonist Therapeutics and 7 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.05 beat Protagonist Therapeutics' score of 0.10 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ardelyx has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

Ardelyx has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$427.68M	3.69	-$61.60M	-$0.23	N/A
Protagonist Therapeutics	$46.02M	145.17	-$130.15M	-$1.81	N/A

Ardelyx has a net margin of -13.58% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Ardelyx currently has a consensus price target of $15.70, suggesting a potential upside of 146.08%. Protagonist Therapeutics has a consensus price target of $113.69, suggesting a potential upside of 9.45%. Given Ardelyx's stronger consensus rating and higher possible upside, research analysts clearly believe Ardelyx is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Ardelyx beats Protagonist Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Ardelyx compare to Cogent Biosciences?

Ardelyx (NASDAQ:ARDX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Ardelyx has higher revenue and earnings than Cogent Biosciences. Ardelyx is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$427.68M	3.69	-$61.60M	-$0.23	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Cogent Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Cogent Biosciences	N/A	-104.27%	-54.64%

In the previous week, Ardelyx and Ardelyx both had 7 articles in the media. Ardelyx's average media sentiment score of 1.05 beat Cogent Biosciences' score of 0.98 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx currently has a consensus price target of $15.70, suggesting a potential upside of 146.08%. Cogent Biosciences has a consensus price target of $43.73, suggesting a potential upside of 27.52%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ardelyx has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

Summary

Ardelyx beats Cogent Biosciences on 10 of the 15 factors compared between the two stocks.

How does Ardelyx compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ardelyx has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A
Ardelyx	$427.68M	3.69	-$61.60M	-$0.23	N/A

Belite Bio has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Belite Bio's return on equity of -19.49% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-19.49%	-19.05%
Ardelyx	-13.58%	-38.11%	-11.85%

In the previous week, Belite Bio had 3 more articles in the media than Ardelyx. MarketBeat recorded 10 mentions for Belite Bio and 7 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.05 beat Belite Bio's score of 0.72 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio currently has a consensus price target of $202.33, suggesting a potential upside of 31.80%. Ardelyx has a consensus price target of $15.70, suggesting a potential upside of 146.08%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Belite Bio has a beta of -1.19, meaning that its share price is 219% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Summary

Ardelyx beats Belite Bio on 12 of the 16 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDX vs. The Competition

Export

Metric	Ardelyx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.63B	$3.04B	$6.30B	$12.20B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-27.74	18.86	21.03	25.58
Price / Sales	3.69	289.31	548.94	78.80
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	10.63	4.35	9.84	6.66
Net Income	-$61.60M	$72.19M	$3.55B	$333.63M
7 Day Performance	-8.60%	-1.05%	-0.52%	-0.12%
1 Month Performance	0.79%	-0.02%	1.21%	3.93%
1 Year Performance	94.51%	46.31%	41.24%	36.07%

Ardelyx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDX Ardelyx	4.3083 of 5 stars	$6.38 -3.5%	$15.70 +146.1%	+88.2%	$1.63B	$427.68M	N/A	90
ACLX Arcellx	2.5141 of 5 stars	$115.07 flat	$111.87 -2.8%	+97.5%	$6.73B	$22.29M	N/A	80	High Trading Volume
KYMR Kymera Therapeutics	2.3747 of 5 stars	$83.59 +3.6%	$118.70 +42.0%	+174.9%	$6.64B	$39.21M	N/A	170	Insider Trade
PTGX Protagonist Therapeutics	1.8044 of 5 stars	$99.52 +1.2%	$108.15 +8.7%	+134.7%	$6.33B	$46.02M	N/A	120	Insider Trade
COGT Cogent Biosciences	3.3063 of 5 stars	$36.73 +0.3%	$43.45 +18.3%	+587.2%	$6.26B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardelyx (ARDX) Competitors

ARDX vs. ACLX, KYMR, PTGX, COGT, and BLTE

How does Ardelyx compare to Arcellx?

Summary

How does Ardelyx compare to Kymera Therapeutics?

Summary

How does Ardelyx compare to Protagonist Therapeutics?

Summary

How does Ardelyx compare to Cogent Biosciences?

Summary

How does Ardelyx compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardelyx (ARDX) Competitors

ARDX vs. ACLX, KYMR, PTGX, COGT, and BLTE

How does Ardelyx compare to Arcellx?

Do analysts recommend ACLX or ARDX?

Is ACLX or ARDX more profitable?

Which has more volatility & risk, ACLX or ARDX?

Do institutionals & insiders have more ownership in ACLX or ARDX?

Which has higher earnings & valuation, ACLX or ARDX?

Does the media prefer ACLX or ARDX?

Summary

How does Ardelyx compare to Kymera Therapeutics?

Do analysts prefer KYMR or ARDX?

Do institutionals & insiders hold more shares of KYMR or ARDX?

Which has better earnings and valuation, KYMR or ARDX?

Is KYMR or ARDX more profitable?

Does the media prefer KYMR or ARDX?

Which has more risk & volatility, KYMR or ARDX?

Summary

How does Ardelyx compare to Protagonist Therapeutics?

Does the media favor ARDX or PTGX?

Do institutionals and insiders hold more shares of ARDX or PTGX?

Which has more risk and volatility, ARDX or PTGX?

Which has higher earnings and valuation, ARDX or PTGX?

Is ARDX or PTGX more profitable?

Do analysts rate ARDX or PTGX?

Summary

How does Ardelyx compare to Cogent Biosciences?

Which has stronger valuation & earnings, ARDX or COGT?

Is ARDX or COGT more profitable?

Does the media favor ARDX or COGT?

Do analysts rate ARDX or COGT?

Do institutionals and insiders hold more shares of ARDX or COGT?

Which has more risk & volatility, ARDX or COGT?

Summary

How does Ardelyx compare to Belite Bio?

Do insiders & institutionals hold more shares of BLTE or ARDX?

Which has higher valuation and earnings, BLTE or ARDX?

Is BLTE or ARDX more profitable?

Does the media refer more to BLTE or ARDX?

Do analysts recommend BLTE or ARDX?

Which has more volatility and risk, BLTE or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools